Concept Life Sciences Appoints New Group Head of Toxicology
News Oct 12, 2017
Concept Life Sciences (Concept) announced it has appointed Marc Princivalle as Group Head of Toxicology, to support the growth of the Company’s integrated discovery and development services.
In this new role, Marc will lead the group’s toxicology and safety team, driving Concept’s expansion into areas such as de-risking pre-clinical candidate selection, investigation of safety and toxicology in the early stages of small molecule discovery is becoming increasingly important to aid successful downstream development.
Marc has over 16 years’ experience in toxicology, with expertise in peptides, small molecule and monoclonal antibodies for various indications such as diabetes, oncology, urology, gynaecology, infertility and dermatology. Marc also has cross-industry experience, having worked in senior toxicology roles in cosmetics, fragrances, over-the-counter medicines, tobacco products and e-Cigarettes, as well as drug discovery and development. Marc has a PhD in Biochemistry from the Geneva University Hospital in the field of Reproductive Medicine, and is a European Registered Toxicologist.
Paul Doyle, Chief Scientific Officer, Concept Life Sciences, said: “Marc’s appointment brings invaluable expertise and experience to Concept, supporting our mission across the group of delivering knowledge-based and science-led solutions to customers, and bringing safety considerations early into the discovery process. We are delighted to welcome him at an exciting point in the Company’s growth, as we continue to establish Concept Life Sciences as leading experts in integrated discovery and development.”
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE